Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPA1 | O75762 | 1/20 | 0.37 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
| ▸ | MAOB | P27338 | 2/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 2/20 | 0.33 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.33 |
| ▸ | TCF7 | P36402 | 1/20 | 0.33 |
| ▸ | CDC7 | O00311 | 1/20 | 0.33 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.33 |
| ▸ | ERCC1 | P07992 | 1/20 | 0.33 |
| ▸ | ERCC4 | Q92889 | 1/20 | 0.33 |
| ▸ | STIM1 | Q13586 | 1/20 | 0.32 |
| ▸ | ORAI1 | Q96D31 | 1/20 | 0.32 |
| ▸ | AR | P10275 | 2/20 | 0.32 |
| ▸ | MAOA | P21397 | 1/20 | 0.32 |
| ▸ | DRD4 | P21917 | 1/20 | 0.31 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.31 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | CACNA1H | O95180 | 1/20 | 0.30 |
| ▸ | HTR2A | P28223 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25411271 | 0.85 | TRPA1 (0.40) | TRPA1APPMAOBNOTUMCTNNB1 | |
| SCHEMBL15551227 | 0.79 | NOTUM (0.34) | TRPA1MAOBNOTUMCTNNB1TCF7 | |
| SCHEMBL20719306 | 0.70 | HTR2A (0.37) | NOTUMCACNA1HHTR2AHTR2C | |
| SCHEMBL25859519 | 0.69 | HTR2C (0.57) | TRPA1NOTUMERCC1ERCC4MAPK1 | |
| SCHEMBL28904374 | 0.68 | ERCC1 (0.49) | TRPA1APPNOTUMERCC1ERCC4 | |
| SCHEMBL1225425 | 0.68 | TRPA1 (0.35) | TRPA1APPMAOBNOTUMCTNNB1 | |
| SCHEMBL20563529 | 0.68 | CYP2A6 (0.41) | APPMAOBHTR2AHTR2C | |
| SCHEMBL12877854 | 0.67 | MAOB (0.39) | TRPA1APPMAOBNOTUMCTNNB1 | |
| SCHEMBL24195801 | 0.67 | MAOB (0.39) | TRPA1APPMAOBCTNNB1TCF7 | |
| SCHEMBL24196291 | 0.67 | MAOB (0.39) | TRPA1APPMAOBCTNNB1TCF7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| US-20240201205-A1 | METHOD FOR DETECTING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-06-20 | — | — | US | disclosed |
| WO-2024059845-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-03-21 | — | — | WO | disclosed |
| US-8507676-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-08-13 | — | — | US | disclosed |
| EP-2462143-B1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2013-05-29 | — | — | EP | disclosed |
| US-8410264-B2 | Heterocyclic oxime compounds | NOVARTIS AG (CH) | 2013-04-02 | — | — | US | disclosed |
| US-8389526-B2 | 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives | NOVARTIS AG (CH) | 2013-03-05 | — | — | US | disclosed |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2012-11-29 | — | — | US | disclosed |
| EP-2467383-A1 | HETEROCYCLIC OXIME COMPOUNDS | Novartis AG (CH) | 2012-06-27 | — | — | EP | disclosed |
| EP-2462143-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | Novartis AG (CH) | 2012-06-13 | — | — | EP | disclosed |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-03-17 | — | — | US | disclosed |
| WO-2011020861-A1 | HETEROCYCLIC OXIME COMPOUNDS | NOVARTIS AG (CH) | 2011-02-24 | — | — | WO | disclosed |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | NOVARTIS AG (CH) | 2011-02-17 | — | — | US | disclosed |
| WO-2011015652-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES AS C-MET TYROSINE KINASE MODULATORS | NOVARTIS AG (CH) | 2011-02-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240199604-A1 | SUPRAMOLECULAR POLYMER THERAPEUTICS AND DIAGNOSTICS | MAPT, HTT, PSEN1 | TRPA1 1993/4885APP 10/4885MAOB 3757/4885 |
| US-20110039831-A1 | 3-HETEROARYLMETHYL-IMIDAZO[1,2-B]PYRIDAZIN-6-YL DERIVATIVES | MET, ERBB2, ABL1 | TRPA1 3882/4885APP 3544/4885MAOB 1174/4885 |
| US-20110065708-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | TRPA1 3650/4885APP 2650/4885MAOB 112/4885 |
| US-20120302570-A1 | HETEROCYCLIC OXIME COMPOUNDS | MET, ERBB2, TIE1 | TRPA1 3650/4885APP 2650/4885MAOB 112/4885 |
| US-20240197682-A1 | METHOD FOR TREATING NEUROLOGICAL DISEASES USING SUPRAMOLECULE POLYMER THERAPEUTICS | PRNP, PSEN1, SNCA | TRPA1 2426/4885APP 5/4885MAOB 2078/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.